Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio

Eli Lilly is adding three new preclinical candidates to its immune and inflammatory medicines armory through TRexBio, a Bay Area biotech that specializes in T regulatory cells, or Tregs.

In exchange for global licenses on the candidates — TRB-051, TRB-031, and TRB-041 — TRexBio will get $55 million upfront. All...

Click to view original post